Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 in schizophrenia
NCT07225712Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ulotaront in schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Dec 2025; status: recruiting.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07225712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225712.